/PRNewswire/ Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) ("Cipla") announced that it has received final approval for its Abbreviated New Drug Application.
NEW YORK CITY (dpa-AFX) - Cipla Limited has received final approval for its Abbreviated New Drug Application for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the FDA. Cipla's Lenalidomide
HYDERABAD, India & PRINCETON, N.J. (BUSINESS WIRE) $RDY #Affordablemedicines Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch, in the U.S. market, of Lenalidomide Capsules, a therape.